The Role of Specialty Drugs in Private Sector Healthcare Spending

Published in: The American Journal of Pharmacy Benefits, v. 5, no. 6, Special Issue, 2013, p. SP23-SP27

Posted on RAND.org on January 01, 2013

by Seth A. Seabury, Dana P. Goldman, Darius N. Lakdawalla

Read More

Access further information on this document at www.ajmc.com

This article was published outside of RAND. The full text of the article can be found at the link above.

OBJECTIVE: The use of specialty drugs is controversial because of their comparatively high cost. However, the extent to which containing cost growth in specialty drugs would contribute to aggregate healthcare savings is unclear. STUDY DESIGN: Retrospective analysis of medical and pharmacy claims from a large, private sector claims database from 2000 to 2009. METHODS: We estimated the share of medical, pharmacy, and total expenditures attributable to specialty drugs for all patients, and for patients taking specialty drugs. To better understand the patterns of specialty drug use for at-risk patients, we computed the share of spending on specialty drugs for patients in the top 25th, 10th, 5th, and 1st percentiles of spending. RESULTS: We found that 1.6% of all patients used a specialty drug, accounting for 2.8% of total spending and 9.3% of pharmacy spending from 2000 to 2009. While specialty drug use was more common for patients in the highest cost groups, the share of spending attributed to the specialty drugs remained modest (no more than 5.6%). Spending on specialty drugs grew from 1.0% of total spending in 2000 to 3.7% in 2009. At current growth rates, our estimates suggest that even the complete elimination of specialty drugs would stave off less than a year's worth of healthcare cost growth over the next decade. CONCLUSIONS: Specialty drugs account for a modest share of total healthcare spending, even among the highest cost patients. Even dramatic reductions in spending on specialty drugs would have only a modest effect on total healthcare costs.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/principles.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.